<p>Dr. Robert Gilman of A.B. PRISMA in Peru proposes to develop a rapid method of evaluating treatment response to tuberculosis and multidrug-resistant TB by measuring exhaled nitric oxide. Preliminary data has shown that patients with MDR-TB exhibit elevated levels of FeNO, and identifying these patients early can lead to alternative treatments to reduce transmission.</p>


Dr. Robert Gilman of A.B. PRISMA in Peru proposes to develop a rapid method of evaluating treatment response to tuberculosis and multidrug-resistant TB by measuring exhaled nitric oxide. Preliminary data has shown that patients with MDR-TB exhibit elevated levels of FeNO, and identifying these patients early can lead to alternative treatments to reduce transmission.